EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study

Hongyan Tong, Zenghua Lin, Chen Yang, Xiaoqin Wang, Jing Sun, Linghui Xia, Jane Shi, Dayu Shi, Zilu Zhang, Anita Appius, Guangsheng He iD

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-07129-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Hongyan Tong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310003, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Complement Inactivating Agents, Hemoglobinuria, Paroxysmal. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease with limited treatment options. The COMMODORE 2 study demonstrated that the novel C5 inhibitor crovalimab had comparable safety and non-inferior efficacy to eculizumab. We evaluated the safety and efficacy of crovalimab compared with eculizumab in the Chinese subpopulation of the global COMMODORE 2 study. Adult patients with PNH without previous complement inhibitor therapy were randomized (2:1) to crovalimab or eculizumab for 24 weeks. The co-primary endpoints were the proportions of patients achieving hemolysis control from Weeks 5–25 and those with transfusion avoidance from baseline to Week 25. The secondary endpoints included the proportion of patients with breakthrough hemolysis and hemoglobin stabilization from baseline to Week 25 and the mean change from baseline in FACIT-Fatigue score at Week 25. Safety data were assessed from baseline to the clinical cut-off (16 November 2022). The demographic and baseline characteristics of the 81 patients included (eculizumab: 27; crovalimab: 54) were well-balanced. In the crovalimab and eculizumab arms, respectively, hemolysis control was achieved in 88.3% and 86.8%, transfusion avoidance in 72.2% and 74.1%, hemoglobin stabilization in 72.2% and 70.4%, and breakthrough hemolysis in 5.6% and 11.1%. The FACIT-Fatigue score improvement was greater with crovalimab. Adverse events (81.5% vs. 88.9%) and grade 3–5 adverse events (24.1% vs. 33.3%) were less frequent with crovalimab. Over 24 weeks, 91% of patients achieved complete terminal complement inhibition with crovalimab. Crovalimab demonstrated at least comparable treatment performance and acceptable safety in Chinese patients with PNH. Clinical trial registration ClinicalTrials.gov identifier NCT04434092 (study registration was first posted on 16th June 2020).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedComplement Inactivating AgentsHemoglobinuria, ParoxysmalAdultAgedFemaleHumansMaleMiddle AgedChinaComplement C5HemolysisTreatment Outcome

Stichwörter der Autor:innen

ChinaCrovalimabEculizumabParoxysmal nocturnal hemoglobinuria

Substanzen

Antibodies, Monoclonal, HumanizedComplement C5Complement Inactivating AgentsCrovalimabeculizumab

Autor:innen und Institutionen

  • Department of Hematology, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, China.
  • Department of Hematology, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
  • Department of Hematology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
  • Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
  • Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

ORCID-Profile: Guangsheng He

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Tong, H., Lin, Z., Yang, C., Wang, X., Sun, J., Xia, L., Shi, J., Shi, D., Zhang, Z., Appius, A., & He, G. (2026). Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07129-3

Vancouver

Tong H, Lin Z, Yang C, Wang X, Sun J, Xia L, et al. Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study. Annals of Hematology. 2026. doi:10.1007/s00277-026-07129-3

BibTeX
@article{Tong2026,
  author = {Tong, Hongyan and Lin, Zenghua and Yang, Chen and Wang, Xiaoqin and Sun, Jing and Xia, Linghui and Shi, Jane and Shi, Dayu and Zhang, Zilu and Appius, Anita and He, Guangsheng},
  title = {Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07129-3}
}
Kostenlos starten →